Silo Pharma Shares Surge on Patent Approval News

Investing.com -- Silo Pharma, Inc. (NASDAQ:SILO) shares surged over 130% in early Wednesday trading following the announcement that the company received a Notification from the U.S. Patent and Trademark Office (USPTO) for a patent application for its primary asset, SPC-15. SPC-15 is an intranasal treatment for post-traumatic stress disorder (PTSD).

The patent, which is expected to be officially granted within the next 90 days, will strengthen the protection of SPC-15 by adding new claims to the existing patent awarded in February 2023. This Notification marks a significant milestone for Silo Pharma, expanding its intellectual property rights and potentially strengthening its market position.

Silo's CEO, Eric Weisblum, commented on the development: "We are pleased to begin 2025 with this anticipated addition to our intellectual property portfolio. The approval of this patent extends protection for SPC-15 and enhances our technology rights." The approval of the patent is seen as a strategic advancement for Silo Pharma, which has a special licensing agreement with Columbia University to develop, manufacture, and commercialize SPC-15 globally.

The company's portfolio is bolstered by existing patents and pending intellectual property applications obtained through its agreement with Columbia University, indicating a robust framework for protecting its primary asset. This move is likely to reinforce investor confidence in Silo's potential to secure technological advancements and navigate the competitive landscape of PTSD treatments.

The market's reaction to this news reflects the high value investors place on strong patent portfolios for companies in the biopharmaceutical sector, where intellectual property is a key asset. The official granting of the patent will be a significant step in securing protection for Silo's proprietary treatment and could have a lasting impact on the company's growth trajectory.